Titanium dioxide nanotubes as drug carriers for infection control and osteogenesis of bone implants
Titanium implants have been widely used as one of the most effective treatments of bone defects. However, the lack of osteogenesis and bacteria-resistant activities result in high infection and loosening rates of titanium implants. Anodic oxidation could easily construct titanium dioxide nanotubes (TNTs) array on the surface of titanium, and the rough surface of TNTs is beneficial to the growth of osteoblast-related cells on the surface. And TNTs could be excellent drug carriers because of their single-entry tubular hollow structure. In this review, we aim at detailing the application of TNTs as drug carriers in the field of bone implants. Starting from the topography of TNTs, we illustrated the biological activity of the TNTs surface, the drugs for loading in TNTs, and the controlled and responsive release strategies of drug-loaded TNTs, respectively. At the end of this review, the shortcomings of TNTs as the drug carrier in the field of bone implants are discussed, and the development direction of this research field is also prospected.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Drug delivery and translational research - 11(2021), 4 vom: 03. Aug., Seite 1456-1474 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Kun [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.04.2022 Date Revised 07.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s13346-021-00980-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324952627 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324952627 | ||
| 003 | DE-627 | ||
| 005 | 20231225191417.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13346-021-00980-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM324952627 | ||
| 035 | |a (NLM)33942245 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Kun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Titanium dioxide nanotubes as drug carriers for infection control and osteogenesis of bone implants |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.04.2022 | ||
| 500 | |a Date Revised 07.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Titanium implants have been widely used as one of the most effective treatments of bone defects. However, the lack of osteogenesis and bacteria-resistant activities result in high infection and loosening rates of titanium implants. Anodic oxidation could easily construct titanium dioxide nanotubes (TNTs) array on the surface of titanium, and the rough surface of TNTs is beneficial to the growth of osteoblast-related cells on the surface. And TNTs could be excellent drug carriers because of their single-entry tubular hollow structure. In this review, we aim at detailing the application of TNTs as drug carriers in the field of bone implants. Starting from the topography of TNTs, we illustrated the biological activity of the TNTs surface, the drugs for loading in TNTs, and the controlled and responsive release strategies of drug-loaded TNTs, respectively. At the end of this review, the shortcomings of TNTs as the drug carrier in the field of bone implants are discussed, and the development direction of this research field is also prospected | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antibacterial | |
| 650 | 4 | |a Controlled release | |
| 650 | 4 | |a Drug delivery | |
| 650 | 4 | |a Orthopedic implants | |
| 650 | 4 | |a Osteogenesis | |
| 650 | 4 | |a Titanium dioxide nanotubes | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a titanium dioxide |2 NLM | |
| 650 | 7 | |a 15FIX9V2JP |2 NLM | |
| 650 | 7 | |a Titanium |2 NLM | |
| 650 | 7 | |a D1JT611TNE |2 NLM | |
| 700 | 1 | |a Jin, Haoyu |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Huo, Jingjing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Peng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug delivery and translational research |d 2011 |g 11(2021), 4 vom: 03. Aug., Seite 1456-1474 |w (DE-627)NLM207177104 |x 2190-3948 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:4 |g day:03 |g month:08 |g pages:1456-1474 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s13346-021-00980-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 4 |b 03 |c 08 |h 1456-1474 | ||